Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01335685 · ClinicalTrials.gov registry record · Phase 1
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT01335685 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 61 participants.
The verdict
NCT01335685, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of this phase 1/2, open-label study was to evaluate the effect of oral formulation of Ixazomib when added to standard melphalan and prednisone (MP) treatment. Both phases of the study included participants who had newly diagnosed multiple myeloma and were ineligible for high-dose therapy plus stem cell transplantation because of age (≥65 years of age) or coexisting conditions and for whom standard MP treatment was indicated.
Interventions
- DRUG Melphalan
- DRUG Prednisone
- DRUG Ixazomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2011-06-27 |
| Est. Completion | 2016-12-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01335685
The ClinicalTrials.gov registry entry for NCT01335685 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Melphalan is the first listed.
NCT01335685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01335685 about?
NCT01335685 is a clinical study titled "Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma". The purpose of this phase 1/2, open-label study was to evaluate the effect of oral formulation of Ixazomib when added to standard melphalan and prednisone (MP) treatment. Both phases of the study included participants who had newly diagnosed multiple myeloma and were ineligible for high-dose therapy...
What is the current status of trial NCT01335685?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2011-06-27. Estimated completion is 2016-12-29.
What interventions are being tested in trial NCT01335685?
The interventions under investigation include: Melphalan (DRUG), Prednisone (DRUG), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT01335685?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.